Key result
Among pacemaker patients with atrial fibrillation, only 28% received anticoagulation therapy, despite only 10.8% of untreated patients having contraindications.
Why the study?
What is the prevalence of anticoagulation use for stroke prevention in pacemaker patients with atrial fibrillation?
Cross-Sectional (n=326)
No
What is the prevalence of anticoagulation use for stroke prevention in pacemaker patients with atrial fibrillation?
The study highlights a significant under-use of indicated anticoagulation therapy for stroke prevention in older pacemaker patients with atrial fibrillation.
Substantial anticoagulation underuse in pacemaker AF patients persists; hypothesis-generating for implementation strategies to close this gap.
This study presents a survey of pacemaker patients followed in a pacemaker clinic. Three hundred and twenty-six patients of mean age 77.7 +/- 9.6 years, 52% female, 75% VVI, 25% dual chamber were analysed. One hundred and forty (43%) were in atrial fibrillation and were older, 80.5 +/- 7.1 years, compared with 75.5 +/- 11.4 years (P = 0.014) for those in sinus rhythm. Temporary pacemaker reprogramming was necessary in 86% in order to determine the abnormal rhythm. Thirty-nine (28%) of those in atrial fibrillation were anticoagulated; 37% were on aspirin; only 10.8% of those in atrial fibrillation who were not anticoagulated had contraindications to this therapy. Prevalence of atrial fibrillation increased with age, whereas that of anticoagulation decreased with age. In conclusion, the majority of pacemaker patients with atrial fibrillation, for whom anticoagulation is indicated, fails to receive it: those caring for these patients are urged to ensure its much wider use.
No takes yet. Share an insight, caveat, or question.
J. Carlsson (2000) conducted a cross-sectional in Atrial fibrillation and pacemaker therapy (n=326). Anticoagulation therapy was evaluated on Anticoagulation use in patients with atrial fibrillation. Among pacemaker patients with atrial fibrillation, only 28% received anticoagulation therapy, despite only 10.8% of untreated patients having contraindications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: